In the last trading session, 1.04 million shares of the Prelude Therapeutics Inc (NASDAQ:PRLD) were traded, and its beta was 1.58. Most recently the company’s share price was $2.60, and it changed around -$0.17 or -6.14% from the last close, which brings the market valuation of the company to $143.05M. PRLD currently trades at a discount to its 52-week high of $6.80, offering almost -161.54% off that amount. The share price’s 52-week low was $1.66, which indicates that the current value has risen by an impressive 36.15% since then. We note from Prelude Therapeutics Inc’s average daily trading volume that its 10-day average is 0.59 million shares, with the 3-month average coming to 211.85K.

Prelude Therapeutics Inc stock received a consensus recommendation rating of Sell, based on a mean score of 3.00. If we narrow it down even further, the data shows that 2 out of 5 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended PRLD as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight.

Prelude Therapeutics Inc (NASDAQ:PRLD) trade information

Instantly PRLD has showed a red trend with a performance of -6.14% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 5.53 on recent trading dayincreased the stock’s daily price by 52.98%. The company’s shares are currently down -39.11% year-to-date, but still down -47.58% over the last five days. On the other hand, Prelude Therapeutics Inc (NASDAQ:PRLD) is -54.94% down in the 30-day period. We can see from the shorts that 2.43 million shares have been sold at a short interest cover period of 12.88 day(s).

The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 56.67% from its current value. Analyst projections state that PRLD is forecast to be at a low of $3 and a high of $10.

Prelude Therapeutics Inc (PRLD) estimates and forecasts

Prelude Therapeutics Inc share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -45.15 percent over the past six months and at a 8.42% annual growth rate that is well below the industry average of 20.10%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -43.14%. Prelude Therapeutics Inc earnings are expected to increase by 9.31% in 2024, but the outlook is positive 30.10% per year for the next five years.

PRLD Dividends

Prelude Therapeutics Inc’s next quarterly earnings report is expected to be released on 2024-Oct-30.

Prelude Therapeutics Inc (NASDAQ:PRLD)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 9.06% of Prelude Therapeutics Inc shares, and 94.11% of them are in the hands of institutional investors. The stock currently has a share float of 103.49%. Prelude Therapeutics Inc stock is held by 91.0 institutions, with ORBIMED ADVISORS LLC being the largest institutional investor. By 2024-06-30, it held 14.4043% of the shares, which is about 10.91 million shares worth $41.56 million.

BAKER BROS. ADVISORS LP, with 13.3673% or 10.12 million shares worth $38.57 million as of 2024-06-30, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund were the top two Mutual Funds as of Jun 30, 2024 . The former held 720.43 shares worth $1.87 million, making up 1.31% of all outstanding shares. On the other hand, Price (T.Rowe) Health Sciences Fund held roughly 620.03 shares worth around $1.61 million, which represents about 1.13% of the total shares outstanding.